(RTTNews.com) - Novartis ( NVS ) said that it will present 33 scientific abstracts at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis or ECTRIMS being held October 10-12, 2018 in Berlin, Germany.
The presentations highlight the company's efforts to advance the understanding of MS and showcase its broad portfolio which addresses different types of MS across patients of all ages.
The abstracts presented at ECTRIMS include studies on Gilenya (fingolimod), oral disease modifying therapy and the only relapsing MS treatment approved in the US for children 10 years of age through to adulthood.
There will also be data for the investigational treatment siponimod (BAF312), the first and only oral drug to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients; and ofatumumab (OMB157), the first self-
administered subcutaneous B-cell therapy for relapsing MS (RMS), which is currently in Phase III development.
Novartis noted that it will also present new data on neurofilaments, protein fragments that are found in the blood at elevated levels in MS patients when damage to neurons occurs. Today, it is possible to measure neurofilaments in the blood and there is growing evidence that demonstrates a strong correlation between their levels
and key measures of MS disease activity.
Utilizing blood neurofilaments as an easy-to-use biomarker for MS could transform clinical trials in the future and allow for disease monitoring in real time in routine clinical practice. Novartis is leading the field with 12 data analyses presented so far.
Multiple sclerosis affects about 2.3 million people worldwide. MS is a chronic disorder of the central nervous system (CNS) that disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss.
Read the original article on RTTNews (http://www.rttnews.com/2942212/novartis-to-present-33-scientific-abstracts.aspx)
For comments and feedback: contact email@example.com